About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, March 11th, 2016

The QualityStocks
Daily Stock List


Monarch America, Inc. (BTFL)

Cannabis Financial Network News, PennyStocks24, Penny Stock Mobsters, WallstreetSurfers, Jet-Life Penny Stocks, and OtcShortReport reported earlier on Monarch America, Inc. (BTFL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Monarch America, Inc. is a fully integrated management and consulting enterprise. The Company delivers trusted high-value products, services, and turnkey solutions to the legal and regulated marijuana and hemp industry. Its mission and vision is to be recognized as one of the nation’s leading, fully integrated cannabis management companies. Monarch America is headquartered in Denver, Colorado.

Monarch America provides complete back office, management, product development and staffing solutions for retail dispensaries. Additionally, the Company provides national branding awareness and vertical integration.
Its MFuze™ is a Trademark, Domain and Service Mark owned by the Company. The creation of MFuzed™ was to provide a licensed brand, allowing entities to license the Mfuze name and to design, develop and manufacture proprietary lines of marijuana infused beverage product.

In addition, HBH Industries, Inc. is a wholly-owned subsidiary of Monarch America. HBH will specialize in cultivation facility leasing, property management, and equipment leasing to the medical and recreational marijuana sector.

Monarch America acquired The Big Tomato, Inc., which is an established Denver region store, warehouse distribution facility, and hydroponics and indoor garden supplier.  Subsequent to the completion of the merger agreement, The Big Tomato is a wholly-owned subsidiary of Monarch America. The Big Tomato is a top supplier of hydroponics and indoor gardening supplies for Denver, Colorado and the surrounding districts.

On the whole, Monarch America’s expectation is to acquire income through providing its management and consulting services to its clients’ cultivation facilities and retail dispensaries. Furthermore, it expects to benefit from the licensing of its proprietary branded infused product lines and the sales from The Big Tomato.

Monarch America announced in September of 2015 that it signed a Letter of Intent (LOI) with Malama Wellness, LLC, developers of a planned medical marijuana business in Hawaii. The LOI anticipates the parties entering into a definitive management consulting agreement. With the agreement, Monarch America will oversee and manage all aspects of a marijuana operation as specified by Malama Wellness in Hawaii.

Regarding Monarch America’s Cultivation Management Services, its experienced staff has over 75 years of experience in establishing, managing, as well as expanding large-scale commercial growing within the cannabis industry.

Monarch America, Inc. (BTFL), closed Friday's trading session at $0.0006, down 14.29%, on 8,158,300 volume with 21 trades. The average volume for the last 60 days is 17,075,651 and the stock's 52-week low/high is $0.0005/$0.21.

PharmaCyte Biotech, Inc. (PMCB)

Stock Market Media Group and Goldman Small Cap Research reported this week on PharmaCyte Biotech, Inc. (PMCB), SmallCapNetwork and OTCJournal did earlier, and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company that centers on developing targeted treatments for cancer and diabetes applying its signature live cell encapsulation technology, Cell-in-a-Box®. This inventive and patented technology is being utilized as a platform upon which treatments for a number of types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built. PharmaCyte Biotech is headquartered in Silver Spring, Maryland.

The live-cell encapsulation technology that the Company uses is a way to enclose living cells in protective “cocoons” around the size of the head of a pin. PharmaCyte encapsulates living cells, not drugs.  Each capsule can enclose roughly 10,000 cells. This number can vary depending upon the size of the cells encapsulated.

The Company is also working towards improving the quality of life of patients with advanced pancreatic cancer and on developing treatments for other types of solid cancerous tumors. It is ready to move into Phase 2b clinical trials in advanced inoperable pancreatic cancer in Australia.

PharmaCyte Biotech’s treatment for pancreatic cancer involves low doses of the recognized anticancer prodrug ifosfamide, together with encapsulated live cells that convert ifosfamide into its active or "cancer-killing" form. These capsules are placed as close to the cancerous tumor as possible. This is to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.

Moreover, PharmaCyte Biotech is developing treatments for cancer founded upon chemical constituents of the Cannabis plant, called cannabinoids. It is examining ways to exploit the benefits of Cell-in-a-Box® technology in optimizing the anticancer effectiveness of cannabinoids, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments.

A study has been published that states that PharmaCyte Biotech’s Melligen cell line could produce insulin in diabetic mice. The Company has the exclusive global rights to use the Melligen cells to treat diabetes.

PharmaCyte Biotech is advancing its new treatment for pancreatic cancer into the clinic in the United States, with study sites in Europe and Australia. The Company’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the U.S.  Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.

In January, PharmaCyte Biotech announced that its CEO, Mr. Kenneth L. Waggoner, and its COO, Dr. Gerald W. Crabtree, recently met with principals of TD2 at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss several aspects related to PharmaCyte Biotech’s forthcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the Food and Drug Administration (FDA) and found acceptable before the clinical trial can start. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct its clinical trial in pancreatic cancer.

PharmaCyte Biotech, Inc. (PMCB), closed Friday's trading session at $0.0665, up 6.40%, on 1,132,981 volume with 224 trades. The average volume for the last 60 days is 1,783,044 and the stock's 52-week low/high is $0.0385/$0.2615.

Andalay Solar, Inc. (WEST)

Street Insider, Penny Stock Circle, 1-2-3 Stock Alerts, Bull Trends, StockMarketQuote.us, StockMister, Fortune Stock Alerts, and Juicy Penny Stocks reported previously on Andalay Solar, Inc. (WEST), and today we report on the Company, here at the QualityStocks Daily Newsletter.

San Jose, California-based Andalay Solar, Inc. is a designer and manufacturer of solar power systems. The Company designs, manufactures, markets, and sells solar power systems and solar panels with integrated micro inverters in the United States and Canada. The design of its products are for use in solar power systems for residential and commercial rooftop customers.  Andalay Solar has more than 30 pending or issued patents related to solar panel installation technology.

In 2007, the Company pioneered the concept of integrating the racking, wiring, and grounding directly into the solar panel. The ground-breaking solar panel was branded "Andalay". In 2009, Andalay Solar launched the first integrated AC solar panel. It reduced the number of components for a rooftop solar installation by roughly 80 percent and lowered labor costs by approximately 50 percent. This AC panel has become the industry's most widely installed AC solar panel. It won the 2009 Popular Mechanics Breakthrough Award.

In 2012, the Company introduced a new generation of products called "Instant Connect®". Currently, it sells its new generation of "Instant Connect®" products in AC and DC format. Andalay sells its products to solar installers, trade workers, and do-it-yourself (DIY) customers by way of distribution partnerships, its dealer network, as well as retail outlets.

Andalay Solar has two new products. One is a DC module with an integrated jumper cable. The other is a smart DC module with a DC optimizer integrated into the j-box. Each of these products incorporate its core innovative plug and play technology with integrated wire management and low profile, rail-less mounting hardware.

Andalay and SolarEdge Technologies, Inc. have agreed to work on developing DC Instant Connect®. This is a solution that will embed the power optimizer cables into the frame of the Andalay module to permit faster cable connection between modules with the aim of eliminating costly wire management issues. In addition, the Company’s Instant Connect® Module is compatible with power optimizers supplied by SolarEdge Technologies. SolarEdge is an international leader in PV inverters, power optimizers, and module-level monitoring services.

The design of Andalay Solar’s licensing strategy for the future is to provide economies of scale to reduce working capital strain and facilitate increased gross margins. This is to enable it to more quickly scale sustainable and accretive growth in revenue, and also eventual profits. It will concentrate on the initiatives related to this, which include partnering with a top 20 residential installer or distributor, partnering with Tier One module companies to license the Andalay technology, including the existing license with Hyundai, and centering on a scalable and lean go-to-market execution plan.

Andalay Solar, Inc. (WEST), closed Friday's trading session at $0.001176, up 17.60%, on 4,713,870 volume with 23 trades. The average volume for the last 60 days is 4,340,434 and the stock's 52-week low/high is $0.0006/$0.017.

Blue Sphere Corp. (BLSP)

PennyStocks24, OTC Stock Review, OTPicks, Penny Stock General, Fast Money Alerts, Stock Shock and Awe, MyBestStockAlerts, SmallCapVoice, and PremiereStockAlerts reported earlier on Blue Sphere Corp. (BLSP), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Blue Sphere Corp. is working to become a key player in the global waste-to-energy and renewable energy markets. Essentially, the Company is a waste-to-energy project integrator. It has a business plan that fits the changing regulatory standards for waste and energy.  A clean-tech waste-to-energy producer, Blue Sphere’s principal business model is BOO (Build-Own-Operate): long-term energy agreements are executed with electric companies in advance of projects. Blue Sphere is based in Charlotte, North Carolina. The Company has operations in the U.S. and Europe.

Blue Sphere is an international business that develops, manages, and owns waste-to-energy projects. The Company is performing waste-to-energy projects in the United States and Italy. Blue Sphere is now centering on projects for which it has signed agreements, term sheets, or memoranda to own and implement such projects and that are in varied stages of development.

The Company is pursuing a strategy to work in association with landfill owners to convert harmful methane gas emissions from landfills into electricity. The process is established on readily available technology already being used in different parts of the U.S. and other regions worldwide. In the U.S., Blue Sphere has its Charlotte, North Carolina Waste to Energy Anaerobic Digester 5.2 MW Plant. In Johnston, Rhode Island, it has its Waste to Energy Anaerobic Digester 3.2 MW Plant.

Blue Sphere, via its wholly-owned subsidiaries, completed the acquisition of four operating biogas facilities in Italy this past December. This represents a major milestone in the Company’s history. Blue Sphere acquired 100 percent of the stock of Agricerere, S.R.L., Agrielektra, S.r.L., Agrisorse, S.r.L. and Gefa, S.r.L.

Individually, each fully operational facility produces one megawatt of electricity per hour, which sells to Gestore del Servizi Energetici GSE, S.p.A., a state owned company that promotes and supports renewable energy sources in Italy, under a Power Purchase Agreement (PPA) that runs through December 31, 2027.

Last month, Blue Sphere announced that it entered into a non-binding Letter of Intent (LOI) with BTPB Holdings BV, a private company incorporated under the laws of the Netherlands (BTPB) to develop a waste-to-energy facility in the Brabant province of the Netherlands. BTPB is establishing an integrated waste solution in Brabant, Holland. BTPB’s intention is to work with Blue Sphere to build and operate a waste-to-energy plant. BTBP Holdings is a unit of Maris Group B.V.  Maris Group operates companies that trade, supply and manufacture process equipment for the chemical, pharmaceutical, mining, energy, agricultural and food industries.

Blue Sphere Corp. (BLSP), closed Friday's trading session at $0.092, up 8.24%, on 631,012 volume with 50 trades. The average volume for the last 60 days is 646,077 and the stock's 52-week low/high is $0.007/$0.0999.

Sigma Labs, Inc. (SGLB)

PennyStocks24 and Pennybuster reported previously on Sigma Labs, Inc. (SGLB), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Sigma Labs, Inc. engages in the development and commercialization of manufacturing and materials technologies, and research and development (R&D) solutions. It is a leading developer of proprietary In-Process Quality Assurance™ (IPQA®) software for additive manufacturing (AM). The OTCQB-listed Company is based in Santa Fe, New Mexico.

By way of its wholly-owned subsidiary, B6 Sigma, Inc., Sigma Labs develops and engineers advanced, in-process, non-destructive quality inspection systems for metal-based additive manufacturing. Sigma Labs consists of leading scientists and engineers from Los Alamos National Laboratory.

Additionally, Sigma Labs serves as an AM contract manufacturer. The Company concentrates on bringing novel and advanced materials and manufacturing technologies out of the nation's top National Labs and into the market to serve the aerospace, defense, biomedical, power generation, and general industrial sectors.

Sigma Labs has current contracts with Federal Government and private industry clients. These contracts are to develop technologies from their conception through the design, building, and testing of prototype systems through integrating sensing, software, materials, and manufacturing technology risk-reduction solutions.

The Company’s methodology will be to commercialize technologies through partnerships, joint development, and licensing with other firms. These technologies include its innovative PrintRite3D® technology. This technology will allow metals parts to be built by 3D printing or additive manufacturing with less flaws and better properties.

This week, Sigma Labs announced that it received a contract from Aerojet Rocketdyne, a subsidiary of Aerojet Rocketdyne Holdings, Inc. (AJRD). The contract is for a non-exclusive license of Sigma Labs’ PrintRite3D® software applications. Sigma Labs’ technology will be used on Aerojet Rocketdyne’s contract with the U.S. Air Force to define standards for qualifying AM components, to be used in liquid-fueled rocket engine applications. The Air Force program is part of a plan to transition away from the Russian-made RD-180 engines now used on the Atlas V launch vehicle.

In addition, Sigma Labs received an order from Aerojet Rocketdyne under the earlier-announced “America Makes” additive manufacturing research project with GE Aviation. The program, financed by the National Additive Manufacturing Innovation Institute (NAMII), employs Sigma Labs’ proprietary In-Process Quality Assurance (IPQA®) software for advanced AM monitoring.

Sigma Labs, Inc. (SGLB), closed Friday's trading session at $0.054, even for the day, on 463,260 volume with 44 trades. The average volume for the last 60 days is 561,299 and the stock's 52-week low/high is $0.0401/$0.80.


The QualityStocks
Company Corner


GTX Corp. (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.0145, up 14.17%, on 396,000 volume with 18 trades. The stock’s average daily volume over the past 60 days is 313,287, and its 52-week low/high is $0.005/$0.023.

GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.

GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.

The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.

As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.

"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer

GTX Corp. Company Blog

GTX Corp. News:

GTX Corp Granted New Communication Protocol Patent Under Family Tree Patent 286

GTX Corp Reports Successful Presentation at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference

GTX Corp to Present at 2nd Annual Innovations Investor Conference and Announces Date of Shareholder Meeting

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.02, up 5.26%, on 2,169,582 volume with 42 trades. The stock’s average daily volume over the past 60 days is 1,353,895 and its 52-week low/high is $0.0035/$0.339.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala

Dominovas Energy Signs Financing Agreement With GHS Capital

Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System

Immune Therapeutics, Inc. (IMUN)

The QualityStocks Daily Newsletter would like to spotlight Immune Therapeutics, Inc. (IMUN). Today, Immune Therapeutics, Inc. closed trading at $0.1716, up 5.28%, on 466,060 volume with 65 trades. The stock’s average daily volume over the past 60 days is 149,310, and its 52-week low/high is $0.045/$0.36.

Immune Therapeutics, Inc. (IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body's natural immune system, the company's pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.

Immune Therapeutics' most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its low dose naltrexone product (LDN), internationally known as Lodonal™, both of which have been shown to stimulate immune systems even in patients with advanced cancer.

Additionally, Immune Therapeutics is pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

Immune Therapeutics and partners AHAR Pharma and GB Pharma Holdings recently completed a bridging trial to determine the safety and efficacy of LDN in patients with HIV, and have submitted data in connection with the filing of its New Drug Application for LDN with The National Agency for Food and Drug Administration and Control, (NAFDAC) of Nigeria. Disclaimer

Immune Therapeutics, Inc. Company Blog

Immune Therapeutics, Inc. News:

Immune Therapeutics, Inc., Appoints Two New Board Members

Immune Therapeutics, Inc to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016

SeeThruEquity Initiates Coverage on Immune Therapeutics, Inc. with a Price Target of $0.61

Lingo Media Corp. (LMDCF)

The QualityStocks Daily Newsletter would like to spotlight Lingo Media Corp. (LMDCF). Today, Lingo Media Corp. closed trading at $0.612, up 0.33%, on 14,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 4,335, and its 52-week low/high is $0.0862/$0.6745.

Lingo Media Corp. (LMDCF) (LM.V) is an EdTech company that's changing the way the world learns English through an innovative combination of proven educational techniques and accessible technology. The company provides both online and print-based solutions through its two distinct business units: ELL Technologies and Lingo Learning. Through ELL Technologies, Lingo has made considerable progress in English-learning markets throughout Latin America. Through print-based publisher Lingo Learning, the company has built a significant presence in the Chinese education market, which includes more than 300 million students.

The company's groundbreaking English programs are developed and marketed for students at every stage of development – from the classroom to the boardroom. This versatility has allowed Lingo to secure contracts and build relationships with clients in a variety of markets around the globe. In Mexico, a subsidiary of the company has partnered with a recognized university that allows it to offer its courses along with certification. In Peru, the company's subsidiary provides its groundbreaking Scholar program to a branch of the country's armed forces.

Through ELL Technologies, Lingo also markets electronic learning solutions that are suitable for pre-readers. Lingo's Kids program – which features cross-platform, multi-browser compatibility – requires no prior knowledge of the English language, allowing the company to address the entire student life cycle in blended learning environments, traditional classroom settings and the home with one cutting-edge solution. The Kids program addresses the critically underserved pre-school market, which includes roughly 181.4 million children across Asia and 30.1 million throughout Latin America and the Caribbean, according to UNESCO.

Although Lingo has traditionally leaned on its print-based offerings as a primary source of revenue, the company's recent efforts to shift into the thriving eLearning market have highlighted the immense potential of a more heavily digital approach. In the second quarter of 2015, Lingo recorded more revenue from digital products than print-based solutions for the first time in its history. With the global eLearning market set to reach $107 billion in 2015, according to a report by Global Industry Analysts, the company's performance and growing foothold in some of the world's most rapidly expanding markets place it in a favorable position. Disclaimer

Lingo Media Corp. Company Blog

Lingo Media Corp. News:

Lingo Media Selected to the 2016 TSX Venture 50 & Ranked #1 In the Diversified Industries Sector

Lingo Media to Present at the World Outlook Financial Conference 2016 on January 29th & 30th

Lingo Media Corp. (LMDCF) (LM.V) Continues to Generate Strong Profits with Q3 Net Income of $631,730

Cherubim Interests, Inc. (CHIT)

The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0001, even for the day, on 1,800,000 volume with 3 trades. The stock’s average daily volume over the past 60 days is 44,726,848, and its 52-week low/high is $0.00001/$0.33.

Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.

The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer

Cherubim Interests, Inc. Company Blog

Cherubim Interests, Inc. News:

Moving Ahead of Averages, Technical Review -- Research on Saleen Automotive, Cherubim Interests, Fission Uranium, and Pure Biosciences

Cherubim Interests, Inc. Signs MOU to Acquire Revenue-Producing Company

Cherubim Interests Inc. Announces FINRA Approval of Convertible Preferred Stock Dividend


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251